Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.
Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Moreno-Martet M, et al. CNS Neurosci Ther. 2014 Sep;20(9):809-15. doi: 10.1111/cns.12262. Epub 2014 Apr 7. CNS Neurosci Ther. 2014. PMID: 24703394 Free PMC article.
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E. Moreno-Martet M, et al. Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5. Mult Scler Relat Disord. 2015. PMID: 26590655
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J. de Lago E, et al. Among authors: moreno martet m. Neuropharmacology. 2012 Jun;62(7):2299-308. doi: 10.1016/j.neuropharm.2012.01.030. Epub 2012 Feb 8. Neuropharmacology. 2012. PMID: 22342378
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.
Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E. Moreno-Martet M, et al. Neurosci Lett. 2012 Feb 6;508(2):67-72. doi: 10.1016/j.neulet.2011.12.020. Epub 2011 Dec 22. Neurosci Lett. 2012. PMID: 22206832
Prospects for cannabinoid therapies in basal ganglia disorders.
Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Fernández-Ruiz J, et al. Among authors: moreno martet m. Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Br J Pharmacol. 2011. PMID: 21545415 Free PMC article. Review.
Cannabinoids, multiple sclerosis and neuroprotection.
de Lago E, Gómez-Ruiz M, Moreno-Martet M, Fernández-Ruiz J. de Lago E, et al. Among authors: moreno martet m. Expert Rev Clin Pharmacol. 2009 Nov;2(6):645-60. doi: 10.1586/ecp.09.42. Expert Rev Clin Pharmacol. 2009. PMID: 22112258
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C. Feliú A, et al. Among authors: moreno martet m. Br J Pharmacol. 2015 Jul;172(14):3579-95. doi: 10.1111/bph.13159. Epub 2015 May 20. Br J Pharmacol. 2015. PMID: 25857324 Free PMC article.